Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haloperidol for Cannabinoid Hyperemesis Syndrome
NCT04176055Phase 4Completed
- Sponsor
- University of Calgary
- Start
- Oct 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of haloperidol in Cannabinoid hyperemesis syndrome (CHS), sponsored by University of Calgary. Primary endpoints: Correlation between quantitative weekly cannabis use and GI symptoms at week 8 and Mean change in GI symptoms from week 8 to week 12. Started Oct 2020; status: completed.
02
Drugs
haloperidol
03
Conditions
Cannabinoid hyperemesis syndrome (CHS)
Beyond the preview
Go deeper on NCT04176055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176055.